A recent study out of Dr. Martin Marsala’s laboratory at the University of California, San Diego School of Medicine showed that Neuralstem’s spinal cord-derived human neural stem cells, NSI-566, had positive benefits in a rat model of spinal cord injury. The rats were treated with the stem cell therapy three days post injury. Eight weeks post treatment, the rats showed significant improvements in motor function, including paw placement, and even showed “amelioration of spasticity.” In April, Neuralstem announced that the FDA approved their Phase II study to inject NSI-566 directly into the spinal cord for the treatment of ALS. To learn more about this trial click here. Also, be sure to watch this informative presentation by Richard Garr, Neuralstem’s CEO and President, from the 8th Annual World Stem Cells & Regenerative Medicine Congress 2013 held in London, UK from May 21-23, 2013. Garr discusses in detail Neuralstem’s Phase I ALS trial results and their next initiatives in ALS.
Click here to read more.Share this: